COVID-19 Vaccineโ Boosts immunotherapy Effectiveness in Lung Cancer โข& Melanoma, โขStudy Finds
GAINESVILLE, FL – Patients with advanced lung cancer or melanoma who received COVID-19 mRNAโค vaccines priorโ to โคstarting immunotherapy treatment lived significantly longer than โขthose whoโ did not,โข according to a new โฃstudy from the โUniversity of Florida (UF Health). The research suggests โขthe vaccines act as โan “internal โขalarm,” priming the immune system to more effectivelyโค recognize and attack cancer cells, and enhancing the impact of โคimmunotherapy.
The study, led by researchers Lin and Sayour, revealed that the mRNA vaccines trigger an immune response that causes tumors โto produce more PD-L1 โข- a molecule that typically shields cancer cells from the body’s defenses. Immunotherapy drugs are specificallyโ designed to block PD-L1, allowing immune cells to attack. The combination of the vaccine-induced immune activation and immunotherapy’s PD-L1 blockade creates a synergistic effect.
“theโค implications are unusual: it could revolutionize the entire field of cancer care,” said Dr. Eliasโ Sayour, Ph.D., pediatric oncologist and co-senior author of the study.”We could design a non-specific vaccine that is even better at mobilizing and resetting the โคimmune response, which could constitute aโ vaccine anticancer global and ready to use for all cancer patients.”
UF Health is preparing a multicenter, randomized phase III clinical trial to investigate integrating mRNA COVID-19 vaccination into the โstandard of care for patients beginning immunotherapy.โ If confirmed, the findings could โrepurpose mRNA vaccine technology – initially developed โฃto โฃcombat viral infections – as a powerful new tool in cancer treatment.